Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma-Reference-Cited by-同舟云学术

Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma

Published:2017-01 Issue:1 Volume:96 Page:e5787
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Zuo Wenli,Zhu Xinghu,Yang Jingke,Mei Zhenyang,Deng Mei,Lin Quande,Song Yongping,Yin Qingsong

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference16 articles.

1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group;Robert;Br J Haematol,2003

2. Three cases of synchronous solid tumor and multiple myeloma;Ji;Cancer Res Treat,2004

3. A case of a combination of multiple myeloma and lung cancer;Osipova;Ter Arkh,1997

4. Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses;Lin;Intern Med (Tokyo, Japan,2010

5. Synchronous presentation of multiple myeloma and lung cancer;Agarwal;J Clin Oncol,2008

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report;Surgical Case Reports;2024-02-07

2. Synchronous multiple myeloma and lung adenocarcinoma: A clinical series;Indian Journal of Pathology and Microbiology;2023-11-09

3. 多発性骨髄腫を合併した進行肺癌に対してレナリドミド，デキサメタゾン療法とペムブロリズマブを併用した1例;Haigan;2023-06-20

4. Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature;Oncology Letters;2022-05-03

The Synchronous Presence of Multiple Myelomas and Other Primary Malignant Tumors: Case Series with Literature Review

;Cancer Management and Research;2020-04